PFIZER's Rx DIFLUCAN ONE-TABLET TREATMENT FOR VAGINAL CANDIDIASIS
This article was originally published in The Tan Sheet
Executive Summary
PFIZER's Rx DIFLUCAN ONE-TABLET TREATMENT FOR VAGINAL CANDIDIASIS represents a new competitive threat to OTC vaginal yeast infection brands, which have been beleaguered in the past year by private-label knock-offs, Pfizer's one-tablet, 150 mg Diflucan (fluconazole) dosage regimen for vaginal candidiasis was approved by FDA on June 30 with a "6P" rating by the agency, denoting a new indication of an already marketed product given a priority review. Pfizer announced the approval on July 7.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning